Company intelligence / Profile preview
CytomX
South San Francisco, California, United Statescytomx.com ↗
- Ownership
- Public · CTMX
- Development stage
- Other
01
Overview
CytomX is advancing multiple Probody therapeutics in the clinic, achieving proof-of-concept for conditional activation of biologics designed for greater tumor selectivity, especially targeting PD-L1 and CD166. The Probody platform demonstrates reduced off-tumor toxicity, with some early-phase efficacy data across various solid tumor types[1][2][3][4].
- Therapeutic areas
- Oncology
- Modalities
- Probody therapeuticsAntibodyAntibody-drug conjugateBiologic
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $466.3M
- Total revenue
- $76.2M
- Enterprise value
- $122.7M
Beyond the preview
Go deeper on CytomX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytomX.